Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 06, 2024 3:29pm
135 Views
Post# 36025582

RE:RE:RE:short interest

RE:RE:RE:short interestI hope there is a huge short interst.
Nothing better than a good old short squeeze.
300,000 shares is very insignificant.
none- the- less, with recent volumes being quite low, could have an effect.
Would be small.
More importantly, much more importantly we need an update of significance, before the scheduled Thursday Q1 update.
Many things on the go. I advise Anyone unsure of what Onc is about, visit the corporate presentation, on the company web site.
Mutiple pieces of information coming due. Anyone of which would result in rapid share price increase.
Shorting ? Not very good odds of $$$ gain.
As with any stock price, there is a downside.
however with an analyst consensus prices well above $6 ps.
even the lowest most conservative has a price of $3ps.
The Nasdaq fair value indicates $4.+++.
Those numbers are extremely cautious & based on assumptions that are expected to happen.
RBC for example includes an upside of $18ps on start of phase 3 and/ or a partnership.
Depending on parameters, a buyout , we have discussed. Any price could pop up.
My point?
shorting has an unlimited upside, AKA huge loss for the short holder.
yet, minimum down side.
short- away, I look forward to the future. Seeing some shorts, loose their pants lol


<< Previous
Bullboard Posts
Next >>